Boron-Containing heterocycles as promising pharmacological agents
Authors:
Top Cited Papers
- 18 April 2022
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 63, 116748
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01AI132614-01A1)
- National Institutes of Health (R21 AA027374-01)
- National Institutes of Health (1R01NS109423-01A1)
This publication has 129 references indexed in Scilit:
- Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetaseScientific Reports, 2013
- Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2013
- SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African TrypanosomiasisPLOS Neglected Tropical Diseases, 2011
- Pediatric Phase I Trial Design Using Maximum Target Inhibition as the Primary EndpointJNCI: Journal of the National Cancer Institute, 2010
- Three Decades of β-Lactamase InhibitorsClinical Microbiology Reviews, 2010
- Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)Best Practice & Research Clinical Endocrinology & Metabolism, 2009
- Recent progress on the topical therapy of onychomycosisExpert Opinion on Investigational Drugs, 2007
- In vitro apoptotic activity of 2,2-diphenyl-1,3,2-oxazaborolidin-5-ones in L5178Y cellsLife Sciences, 2006
- Irreversible Inhibitors of Serine, Cysteine, and Threonine ProteasesChemical Reviews, 2002
- A Mechanism of Drug Action Revealed by Structural Studies of Enoyl ReductaseScience, 1996